European countries struggle to fund new cancer drugs which bring benefits at a high price. Meanwhile billions of euros are wasted, say researchers, because doctors prescribe branded drugs when a generic equivalent is just as good, and because the cost of generics is far too high.
Related Articles
Senza categoria
The neglected magic bullet
Editorial
Fake drugs pose a threat to Europe’s cancer patients
Spotlight on